# RadioMedix, Inc.

> RadioMedix is a Houston biotechnology company developing targeted radiopharmaceuticals for cancer imaging and therapy. Its work includes Detectnet, the investigational lead-212 therapy AlphaMedix, a generic prostate cancer PET agent, the RAHA-100 isotope generator and contract development and manufacturing services.

- **Founded:** 2006
- **Headquarters:** Houston, United States
- **Founders:** Ebrahim S. Delpassand (Founder, Chairman and CEO), Izabela Tworowska (Co-Founder and Chief Scientific Officer), Azar Delpassand (Co-Founder and Board Member)
- **Products:** Detectnet (copper Cu 64 dotatate injection), AlphaMedix (212Pb-DOTAMTATE), Gallium Ga 68 Gozetotide Injection (Ga-68 PSMA-11), RAHA-100, Contract development and cGMP manufacturing
- **Notable:** Detectnet received FDA marketing approval on September 3, 2020., AlphaMedix received FDA Breakthrough Therapy Designation in February 2024 for the specified RLT-naïve GEP-NET population., RadioMedix and Orano Med announced a global AlphaMedix licensing agreement with Sanofi in September 2024.

## Products & services

- **Detectnet (copper Cu 64 dotatate injection)** — FDA-approved PET agent for localization of somatostatin receptor-positive neuroendocrine tumors in adults; developed with commercial partner Curium.
- **AlphaMedix (212Pb-DOTAMTATE)** — Investigational somatostatin receptor-targeted alpha therapy for neuroendocrine tumors; Phase 2 complete, licensed with Orano Med to Sanofi for global commercialization. Not an approved medicine.
- **Gallium Ga 68 Gozetotide Injection (Ga-68 PSMA-11)** — Generic PSMA-targeted PET diagnostic for specified prostate cancer imaging indications; approval announced June 10, 2026.
- **RAHA-100** — Automated radium-224-based lead-212 generator and synthesizing platform; installation, consumables and service support offered.
- **Contract development and cGMP manufacturing** — Radiochemistry, analytical method development, process validation, quality control and clinical-to-commercial manufacturing for academic and industrial partners at the SPICA Center.

## Achievements

- Detectnet received FDA marketing approval on September 3, 2020.
- AlphaMedix received FDA Breakthrough Therapy Designation in February 2024 for the specified RLT-naïve GEP-NET population.
- RadioMedix and Orano Med announced a global AlphaMedix licensing agreement with Sanofi in September 2024.
- Sanofi reported that ALPHAMEDIX-02 met key efficacy endpoints by investigator and independent assessments in October 2025.
- RadioMedix announced generic Ga-68 PSMA-11 approval in June 2026 and reported a manufacturing inspection with no Form 483 observations.

## Latest updates

- **2026-07** — Brian A. Markison appointed to the board, effective July 1; announced July 15.
- **2026-06** — Company announced FDA approval of generic Gallium Ga 68 Gozetotide Injection on June 10.
- **2026-05** — Company announced SNMMI 2026 presentations and its twentieth anniversary.
- **2025-12** — Five-year thorium-228 supply agreements announced with Thor Medical and Van Overeem Nuclear B.V.
- **2025-10** — Sanofi presented Phase 2 AlphaMedix results at ESMO; international Phase 3 planning was described at that time.

## Links

- Website: https://radiomedix.com/
- LinkedIn: https://www.linkedin.com/company/radiomedix-inc-/
- Twitter/X: https://twitter.com/radiomedix
- YouTube: https://www.youtube.com/@RadioMedix
- Facebook: https://www.facebook.com/profile.php?id=100057388010947

---

Profile page: https://yespress.io/radiomedix-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-04